Comparisons of cost-utility analyses for major diseases: A focus in the Australian context

Alan  Silburn

doi:10.59400/ephr2244

Alan Silburn Western Sydney University, Campbelltown 2560, Australia

Article ID: 2244

Keywords: cost-utility analysis; disability-adjusted life years; quality-adjusted life years; potential years of life lost; health economics; disease burden

Abstract

This article delves into the nuances of cost-utility analyses applied to prevalent health conditions, examining the distinctive approaches for lung cancer, ischemic heart disease, and depressive disorders in Australia. The study explores the impact of utility-based units such as Disability-Adjusted Life Years, Quality-Adjusted Life Years, and Potential Years of Life Lost in economic evaluations. Notably, variations in disability weights and their implications on comparability are scrutinized, providing insights into the economic burden and cost-effectiveness of interventions. Findings reveal nuanced evaluation techniques’ critical importance and contextual relevance in health economic assessments.

References

[1]Goodacre S. An introduction to economic evaluation. Emergency Medicine Journal. 2002; 19(3): 198–201. doi: 10.1136/emj.19.3.198

[2]Drummond M, Sculpher M, Torrance GW, et al. Methods for the economic evaluation of health care programmes, 4th ed. Oxford University Press; 2015

[3]Australian Institute of Health and Welfare. Australia’s health 2018. Australian Institute of Health and Welfare; 2018.

[4]Robinson R. Cost-utility analysis. BMJ. 1993; 307(6908): 859–862. doi: 10.1136/bmj.307.6908.859

[5]Robberstad B. QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiologi. 2009; 15(2). doi: 10.5324/nje.v15i2.217

[6]World Health Organization. The global burden of disease : 2004 update. Available online: https://www.who.int/publications/i/item/9789241563710 (accessed on 4 June 2024).

[7]Prieto L, Sacristán JA. Health and Quality of Life Outcomes. 2003; 1(1): 80. doi: 10.1186/1477-7525-1-80

[8]Association of Public Health Epidemiologists in Ontario. Calculating Potential Years of Life Lost (PYLL). Available online: http://core.apheo.ca/index.php?pid=190 (accessed on 4 June 2024).

[9]Aragón TJ, Lichtensztajn DY, Katcher BS, et al. Calculating expected years of life lost for assessing local ethnic disparities in causes of premature death. BMC Public Health. 2008; 8(1). doi: 10.1186/1471-2458-8-116

[10]Murray C, Lopez A. The Global Burden of Disease. Boston: The Harvard School of Public Health; 1996.

[11]Salomon J. New disability weights for the global burden of disease. Bulletin of the World Health Organization. 2010; 88(12): 879–879. doi: 10.2471/blt.10.084301

[12]Global Health Data Exchange. Global Burden of Disease Study 2019 (GBD 2019) Disability Weights | GHDx. Available online: http://ghdx.healthdata.org/record/ihme-data/gbd-2019-disability-weights#:~:text=Disability%20weights%2C%20which%20represent %20the (accessed on 4 June 2024).

[13]Cancer Council. Lung cancer. Available online: https://www.cancer.org.au/cancer-information/types-of-cancer/lung-cancer (accessed on 4 June 2024).

[14]Goldsbury DE, Weber MF, Yap S, et al. Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. PLOS ONE. 2020; 15(8): e0238018. doi: 10.1371/journal.pone.0238018

[15]Lung Foundation Australia. Impact of lung disease. Lung Foundation Australia; 2021.

[16]Australian Institute of Health and Welfare. Australian Burden of Disease Study 2015: Interactive data on disease burden, Overview. Australian Institute of Health and Welfare; 2020.

[17]Cancer Australia. Report to the Nation—Lung Cancer 2011. Sydney: Cancer Australia; 2011.

[18]Suman M, Suman M, Neha D, et al. Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years. Cancer Biology & Medicine. 2017; 14(1): 74-82. doi: 10.20892/j.issn.2095-3941.2016.0030

[19]Cancer Australia. Report on the Lung Cancer Screening Enquiry. Sydney: Cancer Australia; 2020.

[20]Brims F, McWilliams A, Fong K. Lung cancer screening in Australia: progress or procrastination? Medical Journal of Australia. 2016; 204(1): 4–5. doi: 10.5694/mja15.01109

[21]Australian Institute of Health and Welfare. Deaths in Australia. Canberra: Australian Institute of Health and Welfare; 2020.

[22]Australian Bureau of Statistics. Ischaemic Heart Disease. Available online: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Main+Features100012015?OpenDocument#:~:text=Ischemic%20heart %20disease%20is%20the (accessed on 4 June 2024).

[23]Australian Institute of Health and Welfare. Coronary heart disease. Australian Institute of Health and Welfare; 2020.

[24]Briffa TG, Eckermann SD, Griffiths AD, et al. Cost‐effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia. 2005; 183(9): 450–455. doi: 10.5694/j.1326-5377.2005.tb07121.x

[25]Beyond Blue. Statistics. Beyond Blue; 2020.

[26]Manicavasagar V. A review of depression diagnosis and management. InPsych; 2012.

[27]Huffman JC, Celano CM, Beach SR, et al. Depression and Cardiac Disease: Epidemiology, Mechanisms, and Diagnosis. Cardiovascular Psychiatry and Neurology. 2013; 2013: 1–14. doi: 10.1155/2013/695925

[28]Hirth RA, Chernew ME, Miller E, et al. Willingness to Pay for a Quality-adjusted Life Year. Medical Decision Making. 2000; 20(3): 332–342. doi: 10.1177/0272989x0002000310

[29]Stiles JA, Chatterton ML, Le LKD, et al. The cost-effectiveness of stepped care for the treatment of anxiety disorders in adults: A model-based economic analysis for the Australian setting. Journal of Psychosomatic Research. 2019; 125: 109812. doi: 10.1016/j.jpsychores.2019.109812

[30]Segal L, Twizeyemariya A, Zarnowiecki D, et al. Cost effectiveness and cost-utility analysis of a group-based diet intervention for treating major depression – the HELFIMED trial. Nutritional Neuroscience. 2018; 23(10): 770–778. doi: 10.1080/1028415x.2018.1556896

[31]Baumann M, Stargardt T, Frey S. Cost–Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation. Applied Health Economics and Health Policy. 2020; 18(4): 567–578. doi: 10.1007/s40258-019-00551-x